Manufacturer of late-stage clinical biopharmaceutical products. IPO in June, 2016 (NASDAQ:CLSD).

Developer of an online platform for clinical payments. Acquired by BioClinica on January 19, 2016.

Contego Medical has developed a platform based on the integration of an embolic protection filter and a treatment device into one single catheter.

Provider of genomic and biomedical computing platform intended to empower scientists and clinicians. Acquired by Veritas Genetics in August 2017.

The company’s small-molecule therapies focus on cyclin-dependent kinases and CDKs. IPO in May 2017 (NASDAQ: GTHX).

Developer of injectable controlled release technologies designed to reduce the frequency of dosing for ocular therapies. IPO in September 2020 (NASDAQ: GRAY).

Founded by pediatricians, developing medical content in an educational format embraced by children. Acquired by Falfurrias 2024

Developer of innovative neurodegeneration small-molecules intended to establish a platform for novel drug discovery.Acquired by Bial in October 2020.

Operator of a biopharmaceutical agency intended to offer drugs for the treatment of diabetes and other metabolic disorders.

Developer of health engagement platform intended to connect families to health resources on the smartphone.
